Skip to main content

Duke Immune Profiling Core (DIPC)

Duke Immune Profiling Core logo


The Duke Immune Profiling Core (DIPC) is a Duke School of Medicine and Duke Cancer Center Institute Service Center whose academic home resides in the Department of Surgery. Our overarching mission, "To identify immunologic signatures that predict clinical outcomes," comprises two components. The first is a Service component in which DIPC provides comprehensive, highly standardized, state-of-the-art human immunologic profiling services in support of both intra- and extramural translational research endeavors, including Phase I/II clinical trials. The second DIPC component focuses on Discovery, and utilizes advanced, high-dimensional Core technologies and resources to stimulate novel translational research initiatives that will impact the existing "standard of medical care." With over 28 years of experience in flow cytometry and immune profiling, we are available to support a wide range of services, such as small-scale projects for generating pilot data extending through clinical trial testing. Additionally, our services extend to single-cell proteomics and multiplex immunoassays, study planning, performing experiments, data collection and analysis, and writing support.

Available Services

FY2021 Rates

Y2021 DIPC rates

Equipment and Facilities


BD SORP Symphony A5 (44 colors)


BD SORP LSRFortessa (18 colors)


Luminex MAGPIX



DIPC Leadership

DIPC Staff

  • Jennifer Enzor
  • Twan Weaver
  • Preksha Patel
  • Katelyn Steadman

  • Erin Murray

Selected Achievements


Immune profiling for vaccine trials

  • From a multimillion dollar grant from NIH, DIPC will assess the cellular immune responses of volunteers in a malaria vaccine trials through the Vaccine Trials Evaluation Unit (VTEU).

Immune profiling for cancer immunotherapy trials

  1. Neoadjuvant ipilimumab therapy for non-small cell lung cancer (NSCLC); NCT01820754
  2. Neoadjuvant Pembrolizumab therapy or non-small cell lung cancer; NCT02818920
  3. Evaluation of nivolumab alone versus nivolumab + ipilimumab therapy for recurrent glioblastomas; NCT02017717
  4. Treatment of urothelial cancers with pembrolizumab alone versus pembrolizumab + ACP196 (a BTK inhibitor); IND#124755
  5. Evaluation of anti-tumor reactivities in the lymph node and PBMC of metastatic, castrate-resistant prostate cancer patientsbefore or after receiving treatment with sipuleucel-T; NCT02036918NCT02036918
  6. A randomized trial of Pembrolizumab and radiotherapy verus radiotherapy in high-risk soft tissue sarcoma of the extremity; NCT03092323

Collaborate with Us


Core Staff Contact

Janet Staats
(919) 684-9807

Surgical Oncology Research Facility (SORF)
915 South LaSalle Street Ext.
Room 119/120
Durham, NC 27710